Take Your Trading To The Next Level. Get Started Here!
+1 (949) 514 8188
The FDA’s expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
The FDA’s expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
Archives
Categories
Archives
Recent Posts
Meta
Categories
Calender